The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Get the Name & Ticker Here
Ronald Kirk Huntsman net worth and biography

Ronald Huntsman Biography and Net Worth

R. Kirk Huntsman is a co-founder of our company and has served as our Chief Executive Officer and a director since September 2016. In June 2020, he was elected Chairman of the Board by our board of directors. In 1995, he founded Dental One (now Dental One Partners), which, as President and Chief Executive Officer he grew to become one of the leading DSOs (dental service organizations) in the country, with over 165 practices in 15 states. After a successful sale of Dental One to MSD Capital in 2008 and subsequent merger in 2009 with Dental Care Partners, Mr. Huntsman was appointed in 2010 as Chief Executive Officer of ReachOut Healthcare America, a Morgan Stanley Private Equity portfolio company. In 2012, he founded Xenith Practices, LLC, a DSO focused on rolling up larger independent general dental offices, which were sold in 2015. From January 2014 to September 2015, Mr. Huntsman founded and served as the Chief Executive Officer of Ortho Ventures, LLC, a US distributor of certain pediatric oral appliances with applications for pediatric sleep disordered breathing. Since November 2015, he has served as the Chief Executive Officer of First Vivos, Inc., which is now our wholly owned subsidiary. He was also a founding member of the Dental Group Practice Association (DGPA), now known as the Association of Dental Support Organizations (ADSO). He is the father of Todd Huntsman. He holds a BS degree in finance from Brigham Young University.

What is Ronald Kirk Huntsman's net worth?

The estimated net worth of Ronald Kirk Huntsman is at least $52,250.00 as of December 23rd, 2022. Mr. Huntsman owns 47,500 shares of Vivos Therapeutics stock worth more than $52,250 as of February 7th. This net worth estimate does not reflect any other investments that Mr. Huntsman may own. Learn More about Ronald Kirk Huntsman's net worth.

What is Ronald Kirk Huntsman's salary?

As the CEO of Vivos Therapeutics, Inc., Mr. Huntsman earned a total compensation package of $455,336.00 in 2020. Mr. Huntsman earned a salary of $251,784.00, non-equity compensation of $177,847.00, and other compensation of $25,705.00. Learn More on Ronald Kirk Huntsman's salary.

How do I contact Ronald Kirk Huntsman?

The corporate mailing address for Mr. Huntsman and other Vivos Therapeutics executives is , , . Vivos Therapeutics can also be reached via phone at 866-908-4867 and via email at [email protected] Learn More on Ronald Kirk Huntsman's contact information.

Has Ronald Kirk Huntsman been buying or selling shares of Vivos Therapeutics?

Ronald Kirk Huntsman has not been actively trading shares of Vivos Therapeutics during the last ninety days. Most recently, on Friday, December 23rd, Ronald Kirk Huntsman bought 20,000 shares of Vivos Therapeutics stock. The stock was acquired at an average cost of $0.50 per share, with a total value of $10,000.00. Following the completion of the transaction, the chief executive officer now directly owns 47,500 shares of the company's stock, valued at $23,750. Learn More on Ronald Kirk Huntsman's trading history.

Who are Vivos Therapeutics' active insiders?

Vivos Therapeutics' insider roster includes Bradford Amman (CFO), and Ronald Huntsman (CEO). Learn More on Vivos Therapeutics' active insiders.

Are insiders buying or selling shares of Vivos Therapeutics?

During the last twelve months, Vivos Therapeutics insiders bought shares 2 times. They purchased a total of 28,000 shares worth more than $26,240.00. The most recent insider tranaction occured on December, 23rd when CEO Ronald Kirk Huntsman bought 20,000 shares worth more than $10,000.00. Insiders at Vivos Therapeutics own 11.6% of the company. Learn More about insider trades at Vivos Therapeutics.

Information on this page was last updated on 12/23/2022.

Ronald Kirk Huntsman Insider Trading History at Vivos Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/23/2022Buy20,000$0.50$10,000.0047,500View SEC Filing Icon  
5/31/2022Buy8,000$2.03$16,240.0023,500View SEC Filing Icon  
9/21/2021Buy5,000$4.31$21,550.00View SEC Filing Icon  
8/17/2021Buy5,000$3.00$15,000.0010,500View SEC Filing Icon  
12/23/2020Buy1,000$7.27$7,270.00View SEC Filing Icon  
See Full Table

Ronald Kirk Huntsman Buying and Selling Activity at Vivos Therapeutics

This chart shows Ronald Kirk Huntsman's buying and selling at Vivos Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vivos Therapeutics Company Overview

Vivos Therapeutics logo
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Read More

Today's Range

Now: $1.10
Low: $1.00
High: $1.16

50 Day Range

MA: $0.92
Low: $0.35
High: $1.88

2 Week Range

Now: $1.10
Low: $0.34
High: $3.69

Volume

129,415 shs

Average Volume

5,384,641 shs

Market Capitalization

$27.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.68
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Get the Name & Ticker Here